Implant Survival After Insertion of Bone Level Tapered (BLT) Implant Ø 2.9 mm in the Clinical Practice Setting
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02699866|
Recruitment Status : Active, not recruiting
First Posted : March 4, 2016
Last Update Posted : February 26, 2019
The Straumann Bone Level Tapered (BLT) implant Ø 2.9 mm implant was developed to allow treatment of patients with single tooth gaps of small dimensions in the lateral and central incisor positions in the mandible and in the lateral incisor positions in the maxilla. These positions are reduced-load-bearing compared to more posterior positions.
During this study performance and safety of the Straumann BLT implants Ø 2.9 mm in the clinical practice setting will be investigated.
|Condition or disease||Intervention/treatment||Phase|
|Tooth Loss||Device: BLT Implant Ø 2.9 mm||Not Applicable|
This is a multi-center, prospective, single cohort, post-market clinical follow-up (PMCF) study. The total study duration for each patient should be 12 ± 1 months.
Straumann BLT implants Ø 2.9 mm will be placed in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement, followed by provisional prosthetic loading after 6 ± 2 weeks and by final prosthetic loading 4 ± 1 months after implant placements.
In total 7 visits per patient are scheduled in this study. Implant survival, PES, implant success, bone level changes and adverse events (AEs) will be assessed.
The investigational device is a CE-(Conformité Européenne, meaning European Conformity) marked product. Straumann BLT implants Ø 2.9 mm Roxolid SLActive (sand blasted, large grit, acid etched surface) are available in lengths of 10, 12 and 14 mm.
Four centers in Germany will participate. The study and any amendments will be performed as far as possible according to International Organization for Standardization (ISO) 14155 and conform to the Declaration of Helsinki (last revision Fortaleza 2013) and local legal and regulatory requirements.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multi-Center, Prospective, Single Cohort, Post-Market Clinical Follow-Up (PMCF) Study to Assess Implant Survival After Insertion of Straumann® Bone Level Tapered (BLT) Implant Ø 2.9 mm in the Clinical Practice Setting|
|Study Start Date :||February 2016|
|Estimated Primary Completion Date :||April 30, 2019|
|Estimated Study Completion Date :||June 30, 2019|
Experimental: BLT Implant Ø 2.9 mm
The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.
Device: BLT Implant Ø 2.9 mm
Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
Other Name: Short Diameter Implant (SDI)
- Implant survival at 12 months after implant placement [ Time Frame: 12 months after implant placement ]A "surviving implant" is an implant stably inserted in the subject's jaw bone at the time of assessment.
- Pink esthetic score (PES) at 6 months after implant placement [ Time Frame: 6 months after implant placement ]The PES allows an objective evaluation of peri-implant soft tissue of single tooth implants based on 7 variables and is highly reproducible. Each variable will be assessed using a 0-1-2 scoring system; 0 being the lowest, and 2 being the highest value. The minimum achievable PES is 0 and the maximum score is 14.
- Implant success at 12 months after implant placement [ Time Frame: 12 months after implant placement ]
A "successful implant" is an implant where all of the following success criteria (according to Buser et al., 1992) apply:
- Absence of persisting subjective discomfort such as pain, foreign body perception and/or dysesthesia (painful sensation);
- Absence of recurrent peri-implant infection with suppuration;
- Absence of tactile implant mobility;
- Absence of a continuous peri-implant radiolucency.
- Marginal bone level changes at 12 months after implant placement [ Time Frame: 12 months after implant placement ]An independent expert is contracted to perform the bone level measurements from the X-rays. The vertical bone level is evaluated by measuring the distance from the implant shoulder to the first visible bone contact on the implant. Measurements are taken at the mesial and distal aspects of the implant, and an average value is calculated. Mean bone level changes are computed by subtracting the average bone level at 12 months after implant placement from the average bone level at baseline (implant placement). Hence, negative bone level changes are representing bone loss; vice versa positive changes representing bone gain. Measurements take into account distortion based on changes on the radiograph from the true dimension of the implant.
- Incidence of adverse events and adverse device effects [ Time Frame: Screening, Baseline, 7-14 days after implant placement, 6 weeks after implant placement, 4 months after implant placement, 6 months after implant placement and 12 months after implant placement ]At each visit the Investigator should determine if any adverse events occurred since the last study visit by speaking with the patient and reviewing any dental and medical records. These AEs, along with any AEs from the current study visit, should be documented and reported as described in Section 8 of the protocol. In addition the Investigator should evaluate the status of any ongoing AEs throughout the study.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02699866
|Kieferchirurgische Gemeinschaftspraxis Dr. Dr. Stroink & Kollegen|
|Düsseldorf, Germany, 40210|
|Mainz, Germany, 55128|
|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Mund-Kiefer-Gesichtschirurgie, Plastische Operationen|
|Mainz, Germany, 55131|
|Universitätsklinikum Münster, Klinik für Mund-, Kiefer- und Gesichtschirurgie|
|Münster, Germany, 48149|
|Kieferchirurgische Praxen Hentschel & Herrmann|
|Zwickau, Germany, 08056|
|Principal Investigator:||Keyvan Sagheb, Dr.||Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Mund-Kiefer-Gesichtschirurgie, Plastische Operationen|